Bernard Chiasson
Chief Operating Officer bei NUVO PHARMACEUTICALS INC.
Profil
Bernard Chiasson is currently the Chief Scientific Officer & VP-Operations at Nuvo Pharmaceuticals, Inc. He was previously the Chief Scientific Officer at Aralez Pharmaceuticals Canada, Inc. and held the position of Vice President at Optum Biometrics, Inc. from 2008 to 2011.
From 2012 to 2016, he was the Chief Scientific Officer at Tribute Pharmaceuticals, Inc. Dr. Chiasson received his undergraduate, graduate, and doctorate degrees from Dalhousie University.
Aktive Positionen von Bernard Chiasson
Unternehmen | Position | Beginn |
---|---|---|
NUVO PHARMACEUTICALS INC. | Chief Operating Officer | - |
Ehemalige bekannte Positionen von Bernard Chiasson
Unternehmen | Position | Ende |
---|---|---|
Tribute Pharmaceuticals, Inc.
Tribute Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tribute Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, licensing and management of pharmaceuticals products in Canada. Tribute is committed to providing patients and physicians with clinically proven pharmaceuticals products that treat recognized medical conditions and diseases. Their goal is to provide quality products that improve patient outcomes. Tribute is seeking to expand its product portfolio in Canada through strategic partnerships with other pharmaceutical, biotechnology and specialty pharmaceutical companies interested in gaining market experience in Canada. | Chief Tech/Sci/R&D Officer | 01.01.2016 |
Optum Biometrics, Inc.
Optum Biometrics, Inc. Medical/Nursing ServicesHealth Services Optum Biometrics, Inc. provides health screening services. The company is headquartered in | Corporate Officer/Principal | 01.01.2011 |
TRIBUTE PHARMACEUTICALS CANADA INC | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Bernard Chiasson
Dalhousie University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Aralez Pharmaceuticals Canada, Inc.
Aralez Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Aralez Pharmaceuticals Canada, Inc. operates as a pharmaceutical company which focuses on the acquisition, licensing, development, and promotion of healthcare products. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The company was founded by Peter Roy Riehl and Robert Paul Harris on November 14, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Nuvo Pharmaceuticals, Inc.
Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Optum Biometrics, Inc.
Optum Biometrics, Inc. Medical/Nursing ServicesHealth Services Optum Biometrics, Inc. provides health screening services. The company is headquartered in | Health Services |
Tribute Pharmaceuticals, Inc.
Tribute Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tribute Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, licensing and management of pharmaceuticals products in Canada. Tribute is committed to providing patients and physicians with clinically proven pharmaceuticals products that treat recognized medical conditions and diseases. Their goal is to provide quality products that improve patient outcomes. Tribute is seeking to expand its product portfolio in Canada through strategic partnerships with other pharmaceutical, biotechnology and specialty pharmaceutical companies interested in gaining market experience in Canada. | Health Technology |